$29.0M
+$29.0M this year2 filings since 2026 · latest Debt filed
Cresilon is a Brooklyn-based biotechnology company that develops, manufactures and markets hemostatic medical devices built on a proprietary plant-based hydrogel technology. The gel is supplied in a prefilled syringe, requires no preparation or manual pressure, and stops moderate to severe bleeding in seconds. Its human product TRAUMAGEL received FDA 510(k) clearance in August 2024 and launched nationwide in the U.S. in January 2025; its veterinary product VETIGEL has been used in roughly 65,000 procedures. The company was founded in 2010 by Joe Landolina and manufactures in a 33,000-square-foot facility in Brooklyn's Industry City.
What sets it apart
A plant-based polymer gel that achieves hemostasis in seconds on severe hemorrhage without any preparation or manual pressure, conforming to irregular wound geometries — addressing bleeding that accounts for over 80% of operating-room deaths after major trauma and 91% of potentially survivable battlefield deaths.
An FDA-cleared plant-based hemostatic gel in a prefilled syringe for the temporary external control of moderate to severe bleeding, used by EMS, trauma centers, military and law enforcement.
